[Anti-platelet therapy in patients with acute coronary syndromes].
The basis for different manifestations of acute coronary syndromes (ACS) is a common anatomical substrate represented as dysfunction of endothelium, chronic inflammation and impairment of the surface of atherosclerotic plaque, slowdown of blood flow and forming of intravascular thrombus (atherothrombosis). Close interrelation between the processes of atherogenesis and thromb formation makes reasonable application of long-term anti-thrombotic therapy aimed at secondary prevention of cardio-vascular complications. The leading role in prevention of atherosclerosis is given to anti-platelet drugs that inhibit the function of platelets. Analysis of the results of numerous clinical trials demonstrated that probably there is no need in developing anti-platelets of new generation in order to achieve success in treatment of ACS. It would be reasonable to achieve deeper understanding of the pathologic process and be more insistent in selecting the therapy.